Rivanicline hemioxalate

Rivanicline (RJR-2403) hemioxalate is a neuronal nicotinic receptor agonist. Rivanicline hemioxalate is highly selective for the rat brain cortex nAChRs (K_i = 26 nM, EC₅₀ of 732 nM) and α4β2 subtype (K_i = 26 nM, EC₅₀ = 16 μM). Rivanicline hemioxalate can significantly restore the learning impairment and cognitive dysfunction. Rivanicline hemioxalate can be used for the study of neurodegenerative diseases (such as schizophrenia or Alzheimer's disease)^{[1][2][3][4][5]}. In Vivo:Rivanicline hemioxalate (0-1.2 µmol/kg, s.c., single dose) significantly improves passive avoidance retention after scopolamine (HY-N0296) -induced amnesia and enhanced both working and reference memory in rats with ibotenic acid lesions of the forebrain cholinergic projection system in an 8-arm radial maze^[2].
Rivanicline hemioxalate (75-125 µmol/kg, s.c., single dose) can cause a decrease in body temperature, respiratory rate, Y-maze activity and auditory startle response, but its potency is significantly lower than that of nicotine in mice physiological test battery model^[2].
Rivanicline hemioxalate (2 mg/kg, i.p., single dose) restores the learning ability of mice in impairment of eyeblink conditioning model^[4].